Oncology Research

Papers
(The median citation count of Oncology Research is 9. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-08-01 to 2026-08-01.)
ArticleCitations
Has_circ_0000069 expression in breast cancer and its influences on prognosis and cellular activities53
Comprehensively analyzing the genetic alterations, and identifying key genes in ovarian cancer48
Construction of the panoptosis-related gene model and characterization of tumor microenvironment infiltration in hepatocellular carcinoma43
System analysis based on the T cell exhaustion‑related genes identifies CD38 as a novel therapy target for ovarian cancer38
A novel isoxazole compound CM2-II-173 inhibits the invasive phenotype of triple-negative breast cancer cells36
Long non-coding RNA H19 promotes proliferation in hepatocellular carcinoma cells via H19/miR-107/CDK6 axis34
The role of AFAP1-AS1 in mitotic catastrophe and metastasis of triple-negative breast cancer cells by activating the PLK1 signaling pathway30
The role of LIN28B in tumor progression and metastasis in solid tumor entities28
Prognostic-related genes for pancreatic cancer typing and immunotherapy response prediction based on single-cell sequencing data and bulk sequencing data28
Betulinic acid-mediating miRNA-365 inhibited the progression of pancreatic cancer19
Changes of protein expression during tumorosphere formation of small cell lung cancer circulating tumor cells19
Neoadjuvant intermediate-course versus long-course chemoradiotherapy in T3-4/N0+ rectal cancer: Istanbul R-02 phase II randomized study18
mTORC2 promotes pancreatic cancer progression and parp inhibitor resistance17
Identification of lncRNAs associated with T cells as potential biomarkers and therapeutic targets in lung adenocarcinoma16
Targeting DNA repair for cancer treatment: Lessons from PARP inhibitor trials15
YWHAH activates the HMGA1/PI3K/AKT/mTOR signaling pathway by positively regulating Fra-1 to affect the proliferation of gastric cancer cells15
Deoxynortryptoquivaline: A unique antiprostate cancer agent14
Drug repositioning of disulfiram induces endometrioid epithelial ovarian cancer cell death via the both apoptosis and cuproptosis pathways13
Multi-institutional analysis of cervical esophageal carcinoma patients treated with definitive chemoradiotherapy: TROD 01-005 study13
The anti-oncogenic effect of 17-DMAG via the inactivation of HSP90 and MET pathway in osteosarcoma cells13
A pan-cancer analysis identifies SOAT1 as an immunological and prognostic biomarker13
Solute carrier-related signature for assessing prognosis and immunity in patients with clear-cell renal cell carcinoma12
Thioredoxin domain-containing protein 9 protects cells against UV-B-provoked apoptosis via NF-κB/p65 activation in cutaneous squamous cell carcinoma12
Progress in research on tumor microenvironment-based spatial omics technologies10
COVID-19 vaccine related hypermetabolic lymph nodes on PET/CT: Implications of inflammatory findings in cancer imaging10
Comprehensive molecular analysis to predict the efficacy of chemotherapy containing bevacizumab in patients with metastatic colorectal cancer9
The zinc figure protein ZNF575 impairs colorectal cancer growth via promoting p53 transcription9
Identification of microbial metabolites that accelerate the ubiquitin-dependent degradation of c-Myc9
A Th2-score in the tumor microenvironment as a predictive biomarker of response to Bacillus Calmette Gu閞in in patients with non-muscle invasive bladder carcinoma: A retrospective study9
Review and prospect of immune checkpoint blockade therapy represented by PD-1/PD-L1 in the treatment of clear cell renal cell carcinoma9
Scaffold proteins of cancer signaling networks: The paradigm of FK506 binding protein 51 (FKBP51) supporting tumor intrinsic properties and immune escape9
Comprehensive bioinformatics analysis and experimental validation: An anoikis-related gene prognostic model for targeted drug development in head and neck squamous cell carcinoma9
Tumor neoantigens: Novel strategies for application of cancer immunotherapy9
The SMAD2/miR-4256/HDAC5/p16INK4a signaling axis contributes to gastric cancer progression9
0.4866898059845